How to collaborate with a federal lab on a joint SBIR proposal

Australian innovation teams often arrive with a credible prototype and a wish list for a federal laboratory. The gap is common in advanced manufacturing, medical devices, clean energy and environmental sensing, where firms in Melbourne, Sydney, Brisbane or Adelaide need specialised instruments or modelling. They may already work with CSIRO or ANSTO and expect a U.S. lab to fill the gap. The pragmatic “give it a go” instinct is useful: test quickly, but choose a partner that can make the result bankable.

A joint SBIR proposal works better when the collaboration is designed before the application. The Federal Laboratory Consortium for Technology Transfer connects more than 300 federal laboratories with businesses and researchers through seven regional areas. Its tools expose laboratory capabilities, inventions and licensing routes. A federal lab can contribute equipment, technical judgment, data or prototype development, yet it does not become an automatic co-applicant. The small business remains responsible for delivery and commercialisation, so funding, intellectual property and performance need a clear model.

Start with the right funding and partnership model

Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) are related U.S. funding routes, and the solicitation controls the work. Typically, Phase I tests feasibility, Phase II develops a validated prototype, and Phase III moves toward market without a standard federal award. STTR supports formal small-business and research-institution collaboration, with minimum business shares of 40 per cent of Phase I R&D and 34 per cent of Phase II R&D. Agency requirements vary, so use the current solicitation and confirm details with the agency program manager.

An Australian company generally cannot submit a U.S. SBIR proposal as prime applicant unless it qualifies as a U.S. small business concern. Routes include an eligible U.S. partner, a genuine U.S. operating entity or a subcontract role. A mailbox and a move of intellectual property offshore will not satisfy substance requirements. For an Australian SBIR or state grant, a U.S. federal laboratory may instead be an overseas research partner, subject to local foreign-participation and cost rules.

Agree on the collaboration instrument early: a contract or subaward for defined R&D, a cooperative research and development agreement, or an evaluation licence followed by a commercial licence. Existing intellectual property and government rights may limit what a laboratory can transfer or disclose. Ask the laboratory’s technology transfer office which arrangement its funding and mission allow, and whether the relationship fits the agency’s STTR, procurement or fee-waiver policy.

Match the lab to a solvable technical problem

Start with the technical bottleneck, not the laboratory’s reputation. Search the consortium’s directory, technology locator and available technology listings using several terms, including “remote sensing,” “battery materials,” “biosensor,” “digital twin” and “high-throughput imaging.” The guide to the right lab partner is a useful start, but capability can sit outside the obvious agency or region. A patent listing may signal a licensable asset; a laboratory profile may signal available people and equipment.

Shortlist organisations by comparable projects, platform access, small-business contracting experience and a route to customer validation. Examples include biomedical facilities associated with NIH, measurement science at NIST, energy and materials programmes at Department of Energy laboratories, remote sensing at NASA, agricultural science at USDA, and ocean observation at NOAA. The right match is rarely the institution with the biggest brand. It is the team that can perform the experiment within the schedule.

Before seeking support, check commercial constraints. Does the laboratory own the background technology? Can an Australian company access personnel or data? Are export controls, defence restrictions or human-subject approvals likely? Are costs allowable under the solicitation? Send a two-page concept note naming the technical question, preliminary evidence, required facility, milestones and decision date. This gives the laboratory something concrete to evaluate and prevents a generic request from disappearing into the “not right now” pile.

Define roles before writing the proposal

Define the parties’ roles in a one-page collaboration model. Identify the U.S. prime, Australian company, federal laboratory and any university or state research partner, including legal entities and ownership interests. State who leads each work package, owns foreground intellectual property, can publish and signs the statement of work. If a small business meets the STTR threshold, the allocation should show real control over its work, technical integration and commercialisation, not merely a subcontract passed to the laboratory.

Convert the concept into work packages with deliverables and acceptance criteria. Phase I might test whether a sensor distinguishes target materials; Phase II might require a repeatable prototype, benchmark data and a pilot-ready package. State dependencies, sample sizes, data-quality rules, failure thresholds and go/no-go decisions. A joint statement of work should show which results transfer to the prime’s product roadmap and which remain research outputs. Vague commitments such as “support commercialisation” are not measurable.

Set governance before submission. Appoint a technical lead, technology transfer contact and programme manager for each party, with working sessions and decision reviews. Agree how risks, change requests, conflicts and publication delays are handled. Account for time differences with U.S. agencies and Australian public holidays. Clear ownership and escalation rules prevent a promising result from being lost during reporting, invoicing or export-control review.

Build a credible technical and commercial plan

Write around the agency’s mission and proposed experiment, not the laboratory’s general excellence. Make five things easy to judge: the customer or mission problem, the novel hypothesis, feasibility, the R&D plan and the route to commercialisation. Describe what is demonstrated, what remains uncertain and what the award will resolve. Use the laboratory’s evidence in that logic; a facilities list can distract reviewers from the feasibility question.

Make milestones falsifiable. Replace “improve performance” with a baseline, target, protocol and acceptance threshold, such as sensitivity, energy density, runtime, accuracy or material recovery. Explain sample selection, controls, repeatability and the comparison method. Identify where results support or kill the route, then explain the next experiment if they pass. This shows that the team understands technical risk and gives the laboratory a clear basis for collaboration.

Build the budget from tasks. Obtain written estimates for laboratory work, equipment, travel, materials, consultants, intellectual property costs and subcontractor effort; explain indirect rates and cost share. Do not double-count Australian grants or treat an expression of interest as committed cash. Reviewers care about allowability, economic reasonableness and whether the proposed share is realistic. Explain how AUD/USD movements, GST treatment and U.S. grants-management demands are contained.

Protect intellectual property and test the market

Settle intellectual property and data rights while trust is high. Distinguish background intellectual property from foreground results, and list licences, field-of-use restrictions, publication rights and government rights. A laboratory may require review before disclosure, while the small business needs enough exclusivity to attract customers and investors. If the laboratory holds a licensable invention, clarify whether the proposal uses it, develops around it or seeks an option. Consortium assistance can help identify the appropriate licensing path.

Map the regulatory and quality pathway early. An Australian medical-device company may ultimately need evidence aligned with both TGA and FDA expectations; agricultural, environmental and industrial technologies may need to meet USDA, EPA or OSHA requirements. Note intended use, performance claims and safety obligations, then separate feasibility experiments from later validation. This avoids promising a regulatory-ready product during Phase I and protects the project from a capability that cannot satisfy customer requirements.

Field evidence can strengthen a proposal when performance outside the bench matters. An Italian account of guided wolf observation shows the value of repeatable observation protocols: credible evidence comes from documented conditions and consistent recording, not one dramatic sighting. The same discipline applies to mining, farming, environmental monitoring or defence sensors, where customer-site trials should become technical milestones. Australian operations can provide a proving ground while the proposal names U.S. federal users and commercial customers. Strong commercialisation plans combine a route to market, likely partners, regulatory work, manufacturing scale-up and letters of intent.

Work across borders without losing control

Treat cross-border execution as technical planning. Confirm who employs U.S. small-business personnel, where intellectual property is invented, how ownership changes on success and which entity controls foreign collaborators. Australian legal advisers should review the structure, while export-control and foreign-investment rules may matter for sensitive equipment, biotechnology, encryption or data. A technology control plan may restrict access by foreign persons. Start that review before samples, source code or detailed plans move between facilities.

Administrative readiness can make or break a U.S. award. The team may need U.S. tax forms, banking capability, commercial insurance, cybersecurity controls, procurement registration, audit records and export documentation. The laboratory may invoice as a contractor rather than accept a subaward, so the prime should confirm the mechanism in writing. Currency conversion, Australian GST and staff leave should appear in the cash-flow plan, while grant conflicts and publication approvals should be scheduled before the application deadline.

A practical sequence starts with a capability search, technical conversation, costed collaboration model and red-team review of the solicitation. Test likely objections: Is the collaboration substantive? Is the small-business contribution real? Is technical risk properly scoped? Does the Australian participant add a necessary capability rather than merely lower cost? Once the answers are clear, the narrative, statement of work, budget and commercialisation plan can advance as one package. The strongest proposal is not a collection of impressive résumés; it is a credible chain from a federal mission need to an experiment, an owned result and a funded path into the market.